María Jesús García-Granda

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

Miren Zuazo, Hugo Arasanz, G. Fernández-Hinojal et al. · EMBO Molecular Medicine · 2019 · 216 citations · Full text

Life Sciences, Immunology, Oncology +17

Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles

Ana Bocanegra, Ane Ruiz‐de‐Angulo, Aintzane Zabaleta et al. · Biomaterials · 2018 · 102 citations · Full text

Life Sciences, Immunology, Oncology +16

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer

Ana Bocanegra, G. Fernández-Hinojal, Miren Zuazo-Ibarra et al. · International Journal of Molecular Sciences · 2019 · 74 citations · Full text

Life Sciences, Immunology, Oncology +17

The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity

Carolyn Edwards, Angelica Sette, Carl T. Cox et al. · British Journal of Cancer · 2021 · 17 citations · Full text

Medicine, Immunology, Pharmacology +17

Abstract 930: CB213: A half-life extended bispecific Humabody VH delivering dual checkpoint blockade to reverse the dysfunction of LAG3+PD-1+ double-positive T cells

James Legg, Brian McGuinness, Hugo Arasanz et al. · Cancer Research · 2020 · 11 citations

Life Sciences, Immunology, Oncology +17